13160-09-3

Upstream product

• 95-55-6 2-amino-phenol 
• 59-67-6 nicotinic acid 
• 899137-96-3 C₁₉H₁₆N₂O₂ 
• 10400-19-8 3-pyridinecarbonyl chloride 

Relevant academic research and scientific papers

Smart cleavage reactions: The synthesis of benzimidazoles and benzothiazoles from polymer-bound esters

The preparation of an array of benzimidazoles and benzothiazoles from polymer-bound esters is described. Polymer-bound esters were treated with 2-aminothiophenols or 1,2-phenylenediamines in the presence of a Lewis acid to afford the corresponding benzothiazole or benzimidazole cleavage products. The reaction of 2-aminophenols with the polymer-bound esters failed to give the desired benzoxazole products using this procedure.

Structure–activity relationship investigation of benzamide and picolinamide derivatives containing dimethylamine side chain as acetylcholinesterase inhibitors

A series of benzamide and picolinamide derivatives containing dimethylamine side chain (4a–4c and 7a–7i) were synthesised and evaluated for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activity in vitro. Structure–activity relat

A kind of sphingomyelin synthase inhibitor, its preparation method and application thereof

The invention provides general formula (I) compound of formula, its pharmaceutically acceptable salts or stereoisomers, wherein X, Y, M, Z, R and Ar respectively as defined in the specification. The invention also provides a composition comprising a therapeutically effective amount of at least one of the foregoing general formula (I) compounds of formula, its pharmaceutically acceptable salts or stereoisomers, and the above-mentioned compound, its pharmaceutically acceptable salts or stereoisomers, or the above-mentioned pharmaceutical composition in preparation for the prevention and/or treatment of sphingomyelin level abnormal increase of the disease caused by the use of the medicament. The invention of the general formula (I) compound of formula, its pharmaceutically acceptable salts or stereoisomers, can selectively inhibit sphingomyelin synthase, internal and external pharmacodynamic effects are significant, the safety is high.

COMPOSITIONS AND METHODS FOR THE TREATMENT ANGINA AND CARDIOVASCULAR CONDITIONS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of angina and cardiovascular conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic aneurysm, angina, atherosclerosis, cerebrovascular accident (stroke), cerebrovascular disease, congestive heart failure, coronary artery disease, myocardial infarction (heart attack), peripheral vascular disease, aortic dissection, aortic stenosis, arrhythmia (irregular heartbeat), atrial fibrillation, cardiomyopathy, chest pain, claudication, congenital heart disease.